miR-101 sensitizes A549 NSCLC cell line to CDDP by activating caspase 3-dependent apoptosis

Oncology Letters

Volumn 7, Issue 2, 2014, Pages 461-465

  Yin, Jiqing ^a   Wang, Mingguo ^b   Jin, Cuixiang ^a   Qi, Qingguo ^c  

^a Key Laboratory of Cardiovascular Proteomics of Shandong Province   (China)

^b SHANDONG UNIVERSITY   (China)

^c People's Republic of China   (China)

Author keywords

A549; CDDP; Chemosensitivity; miR 101; miRNA; NSCLC

Indexed keywords

CASPASE 3; CISPLATIN; MICRORNA 101;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MTT ASSAY; NICK END LABELING; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84890379569     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1725     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
3. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol19: 3210-3218, 2001.
4. Lee MW, Kim DS, Min NY and Kim HT: Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin. Int J Cancer 122: 2380-2384, 2008.
5. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
6. Cheng AM, Byrom MW, Shelton J and Ford LP: Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 33: 1290-1297, 2005.
7. Xu P, Guo M and Hay BA: MicroRNAs and the regulation of cell death. Trends Genet 20: 617-624, 2004.
8. Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11: 597-610, 2010.
9. Doench JG and Sharp PA: Specificity of microRNA target selection in translational repression. Genes Dev 18: 504-511, 2004.
10. Bentwich I, Avniel A, Karov Y, et al: Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet37: 766-770, 2005.
11. Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
12. O'Day E and Lal A: MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 12: 201, 2010.
13. Smits M, Nilsson J, Mir SE, et al: miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 1: 710-720, 2010.
14. Semaan A, Qazi AM, Seward S, et al: MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf(1)/cip(1). Pharm Res 28: 3079-3090, 2011.
15. Wang HJ, Ruan HJ, He XJ, et al: MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer 46: 2295-2303, 2010.
16. Pang Y, Young CY and Yuan H: MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) 42: 363-369, 2010.
17. Su H, Yang JR, Xu T, et al: MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 69: 1135-1142, 2009.
18. Zhang JG, Guo JF, Liu DL, Liu Q and Wang JJ: MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol 6: 671-678, 2011.
19. Chen S, Wang H, Ng WL, Curran WJ and Wang Y: Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level. Int J Radiat Oncol Biol Phys 81: 1524-1529, 2011.
20. Batchu RB, Gruzdyn O, Qazi AM, Bouwman D, GruberSA and Weaver DW: MicroRNA-101 (miR-101) enhances chemosensitivity of pancreatic ductal adenocarcinoma (PDAC) cells by inhibition of MTOR signaling via PRAS40. J Surg Res172: 233, 2012.
21. Xu Y, An Y, Wang Y, et al: miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 29: 2019-2024, 2013.
22. Sachdeva M, Wu H, Ru P, Hwang L, Trieu V and Mo YY: MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene 30: 822-831, 2011.
23. Gui T and Shen K: miRNA-101: a potential target for tumor therapy. Cancer Epidemiol 36: 537-540, 2012.
24. Chiang CW, Huang Y, Leong KW, et al: PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells. J Biomed Sci 17: 35, 2010.
25. Buechner J, Tomte E, Haug BH, et al: Tumor-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer 105: 296-303, 2011.
26. Varambally S, Cao Q, Mani RS, et al: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322: 1695-1699, 2008.